EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Engineering a Radiohybrid PSMA Ligand with an Albumin-Binding Moiety and Pharmacokinetic Modulation via an Albumin-Binding Competitor for Radiotheranostics

Saki Hirata, Hiroaki Echigo, Masayuki Munekane iD, Kenji Mishiro iD, Kohshin Washiyama iD, Takeshi Fuchigami iD, Hiroshi Wakabayashi, Kazuhiro Takahashi iD, Seigo Kinuya, Kazuma Ogawa iD

Molecules · 2025

DOI: 10.3390/molecules30132804 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Saki Hirata und 9 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Ishikawa, Japan. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Albumins, Glutamate Carboxypeptidase II, Antigens, Surface. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI, The Mitani Foundation for Research and Development, Terumo life science foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prostate-specific membrane antigen (PSMA) is a well-established target for radiotheranostics in prostate cancer. We previously demonstrated that 4-(p-astatophenyl)butyric acid (APBA), an albumin-binding moiety (ABM) labeled with astatine-211 (211At), enables the modulation of pharmacokinetics and enhancement of therapeutic efficacy when combined with the post-administration of an albumin-binding competitor. However, this strategy has not been explored in PSMA-targeting ligands. We designed and synthesized [211At]6, a novel PSMA ligand structurally analogous to PSMA-617 with APBA. The compound was obtained via a tin–halogen exchange reaction from the corresponding tributylstannyl precursor. Comparative cellular uptake and biodistribution studies were conducted with [211At]6, its radioiodinated analog [125I]5, and [67Ga]Ga-PSMA-617. To assess pharmacokinetic modulation, sodium 4-(p-iodophenyl)butanoate (IPBA), an albumin-binding competitor, was administered 1 h postinjection of [125I]5 and [211At]6 at a 10-fold molar excess relative to blood albumin. The synthesis of [211At]6 gave a radiochemical yield of 15.9 ± 7.7% and a radiochemical purity > 97%. The synthesized [211At]6 exhibited time-dependent cellular uptake and internalization, with higher uptake levels than [67Ga]Ga-PSMA-617. Biodistribution studies of [211At]6 in normal mice revealed a prolonged blood retention similar to those of [125I]5. Notably, post-administration of IPBA significantly reduced blood radioactivity and non-target tissue accumulation of [125I]5 and [211At]6. We found that ABM-mediated pharmacokinetic control was applicable to PSMA-targeted radiotherapeutics, broadening its potential for the optimization of radiotheranostics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsAlbuminsGlutamate Carboxypeptidase IIAntigens, SurfaceProstatic NeoplasmsAnimalsLigandsMiceMaleHumansTissue DistributionAstatineCell Line, TumorIodine RadioisotopesHeterocyclic Compounds, 1-RingDipeptidesProstate-Specific Antigen

Stichwörter der Autor:innen

PSMAalbumin-binding moietyastatine-211radiotheranosticstargeted alpha therapy (TAT)

Substanzen

LigandsRadiopharmaceuticalsAlbuminsGlutamate Carboxypeptidase IIFOLH1 protein, humanAntigens, SurfaceAstatineAstatine-211Iodine RadioisotopesPSMA-617

Autor:innen und Institutionen

  • Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Ishikawa, Japan.
  • Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Fukushima, Japan.
  • Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa University, Takara-machi 13-1, Kanazawa 920-8641, Ishikawa, Japan.

ORCID-Profile: Masayuki Munekane, Kenji Mishiro, Kohshin Washiyama, Takeshi Fuchigami, Kazuhiro Takahashi, Kazuma Ogawa

Förderung

  • JSPS KAKENHI
  • The Mitani Foundation for Research and Development
  • Terumo life science foundation
  • Program of the Network-type Joint Usage/Research Center for Radiation Disaster Medical Sci-ence
  • Program of the Network-type Joint Usage/Research Center for Radiation Disaster Medical Science

Zitieren

APA

Hirata, S., Echigo, H., Munekane, M., Mishiro, K., Washiyama, K., Fuchigami, T., Wakabayashi, H., Takahashi, K., Kinuya, S., & Ogawa, K. (2025). Engineering a Radiohybrid PSMA Ligand with an Albumin-Binding Moiety and Pharmacokinetic Modulation via an Albumin-Binding Competitor for Radiotheranostics. Molecules. https://doi.org/10.3390/molecules30132804

Vancouver

Hirata S, Echigo H, Munekane M, Mishiro K, Washiyama K, Fuchigami T, et al. Engineering a Radiohybrid PSMA Ligand with an Albumin-Binding Moiety and Pharmacokinetic Modulation via an Albumin-Binding Competitor for Radiotheranostics. Molecules. 2025. doi:10.3390/molecules30132804

BibTeX
@article{Hirata2025,
  author = {Hirata, Saki and Echigo, Hiroaki and Munekane, Masayuki and Mishiro, Kenji and Washiyama, Kohshin and Fuchigami, Takeshi and Wakabayashi, Hiroshi and Takahashi, Kazuhiro and Kinuya, Seigo and Ogawa, Kazuma},
  title = {Engineering a Radiohybrid PSMA Ligand with an Albumin-Binding Moiety and Pharmacokinetic Modulation via an Albumin-Binding Competitor for Radiotheranostics},
  journal = {Molecules},
  year = {2025},
  doi = {10.3390/molecules30132804}
}
Kostenlos starten →